Shots:

• The US FDA finalizes its guidance on interchangeability of a biosimilar with its reference biologic- which means it may be substituted without prescriber intervening
• The final guidance provides clarity to the developers that the proposed biological product should meet the interchangeability standard under the Public Health Service Act (PHS Act)
• Till date- the US FDA has licensed 19 Biosimilars as a part of Biosimilars Action Plan- targeted for patients' access to lower-cost options

Ref: US FDA | Image: Wall Street Journal